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ABSTRACT: Following our strategy of coupling cyclin-dependent kinase (Cdk)
inhibitors with organometallic moieties to improve their physicochemical properties and
bioavailability, five organoruthenium complexes (1c−5c) of the general formula [RuCl(η6-
arene)(L)]Cl have been synthesized in which the arene is 4-formylphenoxyacetyl-η6-
benzylamide and L is a Cdk inhibitor [3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-
b]pyridines (L1−L3) and indolo[3,2-d]benzazepines (L4 and L5)]. All of the compounds
were characterized by spectroscopic and analytical methods. Upon prolonged standing
(2−3 months) at room temperature, the dimethyl sulfoxide (DMSO) solutions of 1c and
2c−HCl afforded residues, which after recrystallization from EtOH and EtOH/H2O,
respectively, were shown by X-ray diffraction to be cis,cis-[RuIICl2(DMSO)2(L1)]·H2O
and mer-[RuIICl(DMSO)3(L2−H)]·H2O. Compound 5c, with a coordinated amidine
unit, undergoes E/Z isomerization in solution. The antiproliferative activities and effects
on the cell cycle of the new compounds were evaluated. Complexes 1c−5c are moderately
cytotoxic to cancer cells (CH1, SW480, A549, A2780, and A2780cisR cell lines). Therefore, in order to improve their
antiproliferative effects, as well as their drug targeting and delivery to cancer cells, 1c−5c were conjugated to recombinant human
serum albumin, potentially exploiting the so-called “enhanced permeability and retention” effect that results in the accumulation
of macromolecules in tumors. Notably, a marked increase in cytotoxicity of the albumin conjugates was observed in all cases.
■ INTRODUCTION
Numerous strategies have been developed for the effective
delivery of anticancer drugs to tumor tissue to improve their
selectivity and, consequently, to reduce drug side effects.1−4 By
using passive and active targeting strategies, cancer nano-
therapeutics, based on polymers (polymeric nanoparticles,
micelles, or dendrimers), lipids (liposomes), viruses (viral
nanoparticles), and carbon nanotubes, leads to an enhancement
of the intracellular concentration of drugs in cancer cells,
usually without being blocked by P-glycoprotein, a protein
responsible for multidrug resistance.5 These emerging
approaches, mainly applied to organic anticancer drugs (e.g.,
doxorubicin, paclitaxel),6 have also been used successfully to
deliver inorganic drugs, namely, platinum(II) and platinum(IV)
complexes.7
Serum albumin has been observed to accumulate in solid
tumors and, consequently, has been exploited as a drug-delivery
system,8 involving both albumin conjugates for the delivery of
anticancer agents and albumin nanoparticles for drug
encapsulation. Interestingly, albumin conjugates with metho-
trexate and a doxorubicin derivative and an albumin paclitaxel
nanoparticle (nab-paclitaxel; Abraxane) have been evaluated in
clinical trials.8,9 Albumin conjugates of the platinum(II)
anticancer drug carboplatin were shown to be as, or more,
effective than carboplatin in reducing the tumor size of nude
mice bearing human breast tumors and, in some cases, were less
toxic.10 Even if in a less advanced stage of development, an
organometallic ruthenium compound has also been conjugated
to recombinant human serum albumin (rHSA), with a
considerable increase (ca. 20-fold) in cytotoxicity observed
(see below).11,12
Organometallic ruthenium(II) arene complexes are currently
under intensive investigations as anticancer agents,13−16 with
several groups contributing to their design. Within this frame,
and as part of our ongoing studies on targeted chemotherapy,17
involving the development of inhibitors of upregulated
receptors and growth factors in cancer cells, we have studied
the effect of metal coordination (Ga, Ru, Os, and Cu) of some
cyclin-dependent kinase (Cdk) inhibitors (indolo[3,2-d]-
benzazepines (paullones),18−23 indolo[3,2-c]quinolines,24 and
3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines25) on
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the antiproliferative activity, bioavailability, etc., of the resulting
complexes. The promising effects, e.g., increased solubility in
physiologically relevant media and synergistic effects from
metal and ligand leading to highly cytotoxic species, warrant
further efforts in this area.
Herein, we describe the synthesis and characterization of a
series of new ruthenium arene complexes of the general
formula [RuCl(η6-arene)(L)]Cl (Chart 1), with a modified
arene ligand, 4-formylphenoxyacetyl-η6-benzylamide, that may
be tethered to rHSA and L = 3-(1H-benzimidazol-2-yl)-1H-
pyrazolo[3,4-b]pyridines (L1−L3) and indolo[3,2-d]-
benzazepines (L4 and L5), which are potential Cdk inhibitors.
In order to achieve targeted drug delivery and potentiate the
pharmacological effects of the compounds, conjugation of the
ruthenium moiety to modified rHSA was realized via hydrazone
bond formation according to reported procedure.10 Interest-
ingly, cleavage of the hydrazone bond under acidic conditions
has been exploited for drug release in cancer cells.26,27 The
complexes and their rHSA conjugates have been screened for
antiproliferative activity on different human cancer cell lines,
and the observed effect on the antitumor activity of tethering
these organometallic compounds to rHSA has been discussed.
■ EXPERIMENTAL SECTION
General Details. 3-(1H-Benzimidazol-2-yl)-1H-pyrazolo[3,4-b]-
pyridine (L1),25 3-(1H-benzimidazol-2-yl)-5-bromo-1H-pyrazolo[3,4-
b]pyridine (L2),25 5-bromo-3-(4-methoxymethyl-1H-benzimidazol-2-
yl)-1H-pyrazolo[3,4-b]pyridine (L3),25 9-(pyridin-2-ylmethylidene)-
amino-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one (L4),21 9-
bromo-6-(α-picolylamino)-7,12-dihydroindolo[3,2-d][1]benzazepine
(L5),22 and [RuCl(μ-Cl)(η6-arene)]2 (where arene = 4-formylphenox-
yacetyl-η6-benzylamide)11 were prepared according to published
protocols (Schemes S1−S3 in the Supporting Informtion). Solvents
(ethanol and diethyl ether) were dried using standard procedures.
Syntheses of complexes were performed under an argon atmosphere
using Schlenk techniques. Elemental analysis (C, H, N, Cl, Br, and S)
was performed by the Microanalytical Service of the Institute of
Physical Chemistry of the University of Vienna. Electrospray
ionization mass spectrometry (ESI-MS) spectra were recorded on a
Bruker Esquire 3000 instrument (Bruker Daltonics, Bremen,
Germany) using methanolic solutions of the complexes. Values of
m/z are quoted for the species with the highest natural abundance.
UV−vis spectra were recorded on a Perkin-Elmer Lambda 20 UV−vis
spectrophotometer with samples dissolved in methanol (1c−5c) and
water (4c and 5c) over 24 h. 1H, 13C, and 15N NMR and 15N,1H
HSQC, 13C,1H HSQC, 13C,1H HMBC, 1H,1H COSY, 1H,1H TOCSY,
and 1H,1H ROESY NMR spectra were measured on a Bruker DPX500
(Ultrashield Magnet) in DMSO-d6 ([RuCl(μ-Cl)(η
6-arene)]2,
[RuCl2(η
6-arene)(DMSO)], 1c−5c, and 2c−HCl), D2O (for 4c only
1H NMR), and MeOH-d4 (for 5c only
1H and 1H,1H ROESY NMR)
using standard pulse programs at 500.32 (1H), 125.81 (13C), and 50.70
(15N) MHz. 1H and 13C shifts are referenced relative to the solvent
signals. 2D NMR spectra for 5c were registered at an equilibrium of E/
Z isomers (for a 2-day-old DMSO-d6 solution).
Synthesis of [RuCl2(η
6-arene)(DMSO)]. Red crystals of
[RuCl2(η
6-arene)(DMSO)]·0.5H2O suitable for X-ray diffraction
study have been obtained from a 1% DMSO/H2O solution of
[RuCl(μ-Cl)(η6-arene)]2 upon standing at room temperature for 1
month. An upscaled synthesis of [RuCl2(η
6-arene)(DMSO)] along
with analytical data is given in the Supporting Information.
Synthesis of [RuCl(η6-arene)(L1)]Cl (1c). [RuCl(μ-Cl)(η6-are-
ne)]2·0.5H2O (149.7 mg, 0.17 mmol) and L1 (123 mg, 0.52 mmol)
were heated in ethanol (25 mL) at 85 °C for 1.5 h. The solvent was
evaporated to half of the initial volume, forming a brick-red precipitate
that was removed by filtration and dried in vacuo at 50 °C. Yield:
172.8 mg, 75%. Anal. Calcd for C29H24Cl2N6O3Ru·0.75H2O
(1c·0.75H2O) (Mr = 690.03 g mol
−1): C, 50.48; H, 3.72; N, 12.18;
Cl, 10.28. Found: C, 50.57; H, 3.52; N, 12.01; Cl, 10.20. ESI-MS in
MeOH (positive): m/z 605 [1c − HCl − Cl]+, 641 [1c − Cl]+, 663
[1c − HCl + Na]+. ESI-MS in MeOH (negative): m/z 639 [1c − HCl
− H]−. UV−vis [MeOH; λmax, nm (ε, M−1 cm−1)]: 269 (28 807), 283
(31 573), 289 (32 451), sh 333 (17 493). 1H NMR (500.32 MHz,
DMSO-d6): δ 14.82 (br s, 1H, H1b), 9.88 (s, 1H, H17d), 9.12 (d, 1H, J
= 6.22 Hz, H4a), 8.81 (tr, 1H, J = 6.26 Hz, H8d), 8.78 (d, 1H, J = 5.19
Hz, H6a), 8.10 (dd, 1H, J = 1.84 and 6.82 Hz, H4b), 7.84 (d, 2H, J =
8.83 Hz, H13d + H15d), 7.81 (dd, 1H, J = 1.94 and 6.10 Hz, H7b), 7.57
(dd, 1H, J = 4.62 and 8.21 Hz, H5a), 7.55−7.51 (m, 2H, H5b + H6b),
7.06 (d, 2H, J = 8.72 Hz, H12d + H16d), 6.52 (tr, 1H, J = 5.83 Hz, H2d
or H4d), 6.46 (m, 2H, H2d or H4d + H1d or H5d), 6.33 (br s, 1H, H1d or
Chart 1. Compounds 1c−5c with Atom Numbering Schemes for NMR Spectroscopic Assignment
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H5d), 5.99 (t, 1H, J = 5.67 Hz, H3d), 4.59 (s, 2H, H10d), 4.34 (tr, 2H, J
= 4.62 Hz, H7d).
13C NMR (125.81 MHz, DMSO-d6): δ 191.83
(C17d), 168.09 (C9d), 162.69 (C11d), 153.61 (C8a), 150.73 (C6a),
146.74 (C2b), 141.41 (C9b), 134.90 (C3a), 134.58 (C8b), 132.12 (C13d
+ C15d), 131.51 (C4a), 130.62 (C14d), 125.35 (C5b or C6b), 124.89 (C5b
or C6b), 119.38 (C5a), 117.84 (C4b), 115.66 (C12d + C16d), 113.90
(C7b), 111.76 (C9a), 101.93 (C6d), 85.39 (C2d or C4d), 85.09 (C2d or
C4d), 83.92 (C3d), 82.67 (C1d or C5d), 82.31 (C1d or C5d), 67.19
(C10d), 40.46 (C7d).
15N NMR (50.70 MHz, DMSO-d6): δ 89.5 (N8d).
Orange crystals of cis,cis-[RuIICl2(DMSO)2(L1)]·H2O suitable for X-
ray diffraction study were grown by recrystallization from ethanol of
the product, obtained by the slow evaporation (2−3 months) of a
DMSO solution of 1c.
Synthesis of [RuCl(η6-arene)(L2)]Cl (2c). a. Synthesis of
2c−HCl·H2O. [RuCl(μ-Cl)(η
6-arene)]2·0.5H2O (100 mg, 0.11 mmol)
and L2 (80 mg, 0.26 mmol) were heated in ethanol (20 mL) at 85 °C
for 1.5 h. The solvent was evaporated to half of the initial volume, and
the yellow precipitate of [RuCl(η6-arene)(L2−H)] (2c−HCl) was
removed by filtration and dried in vacuo at 50 °C. Yield: 151.8 mg,
92%. Anal. Calcd for C29H22BrClN6O3Ru·H2O (2c−HCl·H2O) (Mr =
736.97 g mol−1): C, 47.26; H, 3.28; N, 11.40; Cl, 4.81; Br, 10.84.
Found: C, 47.53; H, 2.97; N, 11.16; Cl, 4.90; Br, 11.04. ESI-MS in
MeOH (positive): m/z 721 [2c−HCl + H]
+, 743 [2c−HCl + Na]
+. ESI-
MS in MeOH (negative): m/z 719 [2c−HCl − H]−. 1H NMR (500.32
MHz, DMSO-d6): δ 13.89 (br s, 1H, H1b), 9.87 (s, 1H, H17d), 9.03 (tr,
1H, J = 5.96 Hz, H8d), 8.99 (d, 1H, J = 2.06 Hz, H4a), 8.55 (d, 1H, J =
2.04 Hz, H6a), 8.01 (d, 1H, J = 8.02 Hz, H4b), 7.84 (d, 2H, J = 8.76 Hz,
H13d + H15d), 7.72 (d, 1H, J = 7.54 Hz, H7b), 7.47 (tr, 1H, J = 7.11 Hz,
H5b or H6b), 7.43 (tr, 1H, J = 7.14 Hz, H5b or H6b), 7.13 (d, 2H, J =
8.69 Hz, H12d + H16d), 6.39 (tr, 1H, J = 5.79 Hz, H2d or H4d), 6.25 (d,
1H, J = 5.81 Hz, H1d or H5d), 6.14 (tr, 1H, J = 5.39 Hz, H2d or H4d),
6.06 (m, 2H, H1d or H5d + H3d), 4.75 (dd, 2H, J = 14.49 and 25.44 Hz,
H10d), 4.42 (d, 2H, J = 5.94 Hz, H7d). The yellow crystals of mer-
[RuIICl(DMSO)3(L2-H)]·H2O suitable for X-ray diffraction study
were grown from a EtOH/H2O solution of the product, obtained by
the slow evaporation (2 months) of a DMSO solution of 2c−HCl.
b. Synthesis of 2c·0.5H2O. A total of 37% HCl (24 mg) was added
to 2c−HCl·H2O (130 mg, 0.18 mmol) in ethanol (20 mL). The
suspension was stirred at room temperature for 1 h, and the solvent
was removed under reduced pressure. The residue (2c) was suspended
in diethyl ether, collected by filtration, and dried in vacuo at 50 °C.
Yield: 135 mg, 100%. Anal. Calcd for C29H23BrCl2N6O3Ru·0.5H2O
(2c·0.5H2O) (Mr = 764.42 g mol
−1): C, 45.57; H, 3.16; N, 10.99; Cl,
9.28. Found: C, 45.75; H, 2.86; N, 10.86; Cl, 8.75. ESI-MS in MeOH
(positive): m/z 743 [2c − HCl + Na]+. ESI-MS in MeOH (negative):
m/z 719 [2c − HCl − H]−. UV−vis [MeOH; λmax, nm (ε, M−1
cm−1)]: 256 (18 146), 300 (24 730), 360 (10 018). 1H NMR (500.32
MHz, DMSO-d6): δ 14.42 (br s, 1H, H1b), 9.88 (s, 1H, H17d), 9.22 (br
s, 1H, H4a), 8.88 (tr, 1H, J = 5.77 Hz, H8d), 8.70 (br s, 1H, H6a), 8.06
(d, 1H, J = 7.23 Hz, H4b), 7.84 (d, 2H, J = 8.83 Hz, H13d + H15d), 7.78
(dd, 1H, J = 1.4 and 7.27 Hz, H7b), 7.50 (m, 2H, H5b + H6b), 7.08 (d,
2H, J = 8.75 Hz, H12d + H16d), 6.46 (tr, 1H, J = 5.76 Hz, H2d or H4d),
6.39 (d, 1H, J = 6.35 Hz, H1d or H5d), 6.35 (tr, 1H, J = 4.21 Hz, H2d or
H4d), 6.23 (d, 1H, J = 5.63 Hz, H1d or H5d), 6.04 (t, 1H, J = 5.49 Hz,
H3d), 4.63 (dd, 2H, J = 14.34 and 18.53 Hz, H10d), 4.35 (ddd, 2H, J =
6.06, 15.03, and 22.65 Hz, H7d).
13C NMR (125.81 MHz, DMSO-d6):
δ 191.81 (C17d), 168.07 (C9d), 162.68 (C11d), 155.35 (C8a), 150.43
(C6a), 147.32 (C2b), 141.46 (C9b), 134.49 (C8b), 133.23 (C3a), 132.11
(C13d + C15d), 131.16 (C4a), 130.63 (C14d), 125.05 (C5b or C6b),
124.70 (C5b or C6b), 117.64 (C4b), 115.66 (C12d + C16d), 114.25 (C5a
or C9a), 113.66 (C7b), 112.69 (C5a or C9a), 101.19 (C6d), 85.26 (C2d or
C4d), 84.51 (C2d or C4d), 83.97 (C3d), 83.04 (C1d or C5d), 82.79 (C1d
or C5d), 67.19 (C10d), 40.30 (C7d).
15N NMR (50.70 MHz, DMSO-
d6): δ 123.7 (N1b), 88.6 (N8d).
Synthesis of [RuCl(η6-arene)(L3)]Cl (3c). [RuCl(μ-Cl)(η6-are-
ne)]2·0.5H2O (100 mg, 0.11 mmol) and L3 (91.5 mg, 0.26 mmol)
were heated in ethanol (20 mL) at 85 °C for 1 h. The solvent was
evaporated to one-third of the initial volume, and the yellow
precipitate (3c) that formed was removed by filtration and dried in
vacuo at 50 °C. Yield: 166 mg, 90%. Anal. Calcd for
C31H27BrCl2N6O4Ru·1.5H2O (3c·1.5H2O) (Mr = 826.49 g mol
−1):
C, 45.05; H, 3.66; N, 10.17; Cl, 8.58; Br, 9.67. Found: C, 45.31; H,
3.24; N, 10.06; Cl, 8.30; Br, 9.36. ESI-MS in MeOH (positive): m/z
727 [3c − HCl − Cl]+, 749 [3c − 2HCl + Na]+, 765 [3c − Cl]+, 785
[3c − HCl + Na]+. ESI-MS in MeOH (negative): m/z 726 [3c −
2HCl − H]−, 763 [3c − HCl − H]−. UV−vis [MeOH; λmax, nm (ε,
M−1 cm−1)]: 259 (29 157), 302 (37 725), 361 (16 424). 1H NMR
(500.32 MHz, DMSO-d6): δ 14.03 (br s, 1H, H1b), 9.88 (s, 1H, H17d),
9.46 (s, 1H, H4a), 8.88 (tr, 1H, J = 5.65 Hz, H8d), 8.69 (d, 1H, J = 1.74
Hz, H6a), 8.01 (d, 1H, J = 7.85 Hz, H4b), 7.84 (d, 2H, J = 8.81 Hz, H13d
+ H15d), 7.49 (m, 2H, H5b + H6b), 7.07 (d, 2H, J = 8.68 Hz, H12d +
H16d), 6.45 (tr, 1H, J = 5.65 Hz, H2d or H4d), 6.39 (d, 1H, J = 6.08 Hz,
H1d or H5d), 6.34 (tr, 1H, J = 4.46 Hz, H2d or H4d), 6.23 (d, 1H, J =
6.05 Hz, H1d or H5d), 6.03 (tr, 1H, J = 5.54 Hz, H3d), 4.87 (dd, 2H, J =
12.39 and 16.13 Hz, H10b), 4.63 (dd, 2H, J = 14.74 and 21.11 Hz,
H10d), 4.35 (ddd, 2H, J = 5.88, 15.17, and 19.74 Hz, H7d), 3.39 (s, 3H,
H11b).
13C NMR (125.81 MHz, DMSO-d6): δ 191.81 (C17d), 168.03
(C9d), 162.65 (C11d), 154.91 (C8a), 150.59 (C6a), 147.44 (C2b), 141.69
(C9b), 133.23 (C3a), 132.98 (C8b), 132.10 (C13d + C15d), 131.78 (C4a),
130.62 (C14d), 124.91 (C5b or C6b), 124.63 (C5b or C6b), 124.54 (C7b),
117.22 (C4b), 115.65 (C12d + C16d), 114.31 (C5a or C9a), 112.74 (C5a
or C9a), 101.36 (C6d), 85.24 (C2d or C4d), 84.56 (C2d or C4d), 84.34
(C3d), 83.26 (C1d or C5d), 82.99 (C1d or C5d), 70.13 (C10b), 67.17
(C10d), 57.97 (C11b), 40.30 (C7d).
15N NMR (50.70 MHz, DMSO-d6):
δ 123.8 (N1b), 88.9 (N8d).
Synthesis of [RuCl(η6-arene)(L4)]Cl (4c). [RuCl(μ-Cl)(η6-are-
ne)]2·0.5H2O (100.3 mg, 0.11 mmol) and L4 (80.03 mg, 0.23 mmol)
were heated in ethanol (15 mL) at 85 °C for 3 h. After cooling to
room temperature, the reaction mixture was filtered and evaporated to
a minimum volume. The addition of diethyl ether resulted in the
precipitation of a brown product, which was removed by filtration and
dried in vacuo. Yield: 163 mg, 87%. Anal. Calcd for
C38H31Cl2N5O4Ru·2H2O (4c·2H2O) (Mr = 829.69 g mol
−1): C,
55.01; H, 4.25; N, 8.44. Found: C, 55.04; H, 4.10; N, 8.41. ESI-MS in
MeOH (positive): m/z 758 [4c − Cl]+, 723 [4c − HCl − Cl]+. ESI-
MS in MeOH (negative): m/z 756 [4c − HCl − H]−, 720 [4c −
2HCl − H]−. UV−vis [MeOH; λmax, nm (ε, M−1 cm−1)]: 218 (63
208), sh 251 (42 884), sh 261 (42 361), sh 281 (36 827), sh 289 (35
680), 315 (33 347), 375 (12 616). UV−vis [H2O; λmax, nm (ε, M−1
cm−1)]: sh 216 (54 985), 288 (35 202), sh 313 (27 554), 381 (10
800). 1H NMR (500.32 MHz, DMSO-d6): δ 12.08 (s, 1H, H12′), 10.21
(s, 1H, H5′), 9.87 (s, 1H, H17d), 9.61 (d, 1H, J = 5.25 Hz, H18′), 8.98 (s,
1H, H14′), 8.78 (t, 1H, J = 5.94 Hz, H8d), 8.32−8.27 (m, 2H, H15′ +
H16′), 8.08 (d, 1H, J = 1.93 Hz, H8′), 7.85 (d, 2H, J = 8.84 Hz, H13d +
H15d), 7.84 (m, 1H, H1′ or H17′), 7.80 (dd, 1H, J = 1.15 and 7.73 Hz,
H1′ or H17′), 7.77 (dd, 1H, J = 2.05 and 8.64 Hz, H10′), 7.64 (d, 1H, J =
8.66 Hz, H11′), 7.44 (t, 1H, J = 7.77 Hz, H3′), 7.32 (m, 2H, H2′ + H4′),
7.11 (d, 2H, J = 8.72 Hz, H12d + H16d), 6.17 (t, 1H, J = 5.96 Hz, H3d),
5.95−5.91 (m, 2H, H2d + H4d), 5.76−5.71 (m, 2H, H1d + H5d), 4.69
(dd, 2H, J = 14.94 and 20.42 Hz, H10d), 4.29 (ddd, 2H, J = 5.74, 15.36,
and 33.98 Hz, H7d), 3.61 (s, 2H, H7′).
13C NMR (DMSO-d6, 125.81
MHz): δ 191.78 (C17d), 171.94 (C6′), 168.25 (C9d), 166.55 (C14′),
162.83 (C11d), 156.61 (C18′), 155.53 (C14a′), 145.69 (C9′), 140.41
(C16′), 138.08 (C11a′), 136.19 (C4a′), 135.43 (C12a′), 132.16 (C13d +
C15d), 130.66 (C14d), 129.76 (C15′), 129.05 (C3′), 128.75 (C17′),
127.58 (C1′), 126.68 (C7b′), 124.29 (C2′), 122.89 (C4′), 122.83 (C12b′),
118.86 (C10′), 115.69 (C12d + C16d), 112.55 (C11′), 111.22 (C8′),
108.91 (C7a′), 102.16 (C6d), 88.49 (C1d or C5d), 88.37 (C3d), 85.86
(C2d or C4d; C1d or C5d), 85.80 (C2d or C4d; C1d or C5d), 85.11 (C2d or
C4d), 67.28 (C10d), 39.93 (C7d), 32.32 (C7′).
15N NMR (DMSO-d6,
50.70 MHz): δ 116.38 (N5′), 110.02 (N12′), 88.51 (N8d).
Synthesis of [RuCl(η6-arene)(L5)]Cl (5c). [RuCl(μ-Cl)(η6-are-
ne)]2·0.5H2O (108 mg, 0.12 mmol) and L5 (102.3 mg, 0.25 mmol)
were heated in ethanol (15 mL) at 85 °C for 3 h. After cooling to
room temperature, the reaction mixture was filtered and evaporated to
a minimum volume. Diethyl ether was added, and the yellow-brown
precipitate was collected and dried in vacuo. Yield: 185 mg, 87%. Anal.
Calcd for C38H32BrCl2N5O3Ru·H2O (5c·H2O) (Mr = 876.59 g
mol−1): C, 52.07; H, 3.91; N, 7.99. Found: C, 51.97; H, 3.95; N,
7.73. ESI-MS in MeOH (positive): m/z 825 [5c − Cl]+, 789 [5c −
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HCl − Cl]+. ESI-MS in MeOH (negative): m/z 823 [5c − HCl −
H]−, 786 [5c − 2HCl − H]−. UV−vis [MeOH; λmax, nm (ε, M−1
cm−1)]: sh 230 (43 177), 268 (44 722), 319 (21 929). UV−vis [H2O;
λmax, nm (ε, M
−1 cm−1)]: sh 217 (32 402), sh 237 (26 864), 273 (28
107), 314 (13 462).
a. NMR Characterization of E/Z Isomers in DMSO-d6.
1H NMR
(500.32 MHz, DMSO-d6): E-isomer, δ 12.05 (s, 1H, H12′), 9.87 (s,
1H, H17d), 9.11 (d, 1H, J = 5.56 Hz, H18′), 9.07 (s, 1H, H5′), 8.69 (t,
1H, J = 5.9 Hz, H8d), 8.22 (d, 1H, J = 1.66 Hz, H8′), 8.09 (t, 1H, J =
7.86 Hz, H16′), 7.85 (d, 2H, J = 8.42 Hz, H13d + H15d), 7.83 (d, 1H, J =
7 Hz, H1′), 7.65 (d, 1H, J = 7.87 Hz, H15′), 7.59 (t, 1H, J = 6.64 Hz,
H17′), 7.46 (m, 2H, H3′ + H11′), 7.37 (d, 1H, J = 8.2 Hz, H10′), 7.34 (m,
2H, H2(E)′ + H2(Z)′), 7.26 (d, 1H, J = 7.94 Hz, H4′), 7.09 (d, 2H, J =
8.72 Hz, H12d + H16d), 6.03 (t, 1H, J = 5.74 Hz, H2d or H4d), 5.95 (t,
1H, J = 5.73 Hz, H2d or H4d), 5.90 (d, 1H, J = 6.05 Hz, H1d or H5d),
5.84 (d, 1H, J = 18.4 Hz, H14′), 5.83 (t, 1H, J = 5.59 Hz, H3d), 5.77 (d,
1H, J = 5.88 Hz, H1d or H5d), 5.22 (d, 1H, J = 17.07 Hz, H14′), 4.77 (d,
1H, J = 13.21 Hz, H7′), 4.64 (s, 2H, H10d), 4.09 (d, 2H, J = 6.09 Hz,
H7d), 3.47 (d, 1H, J = 15.25 Hz, H7′).
1H NMR (500.32 MHz, DMSO-
d6): Z isomer, δ 11.85 (s, 1H, H12′), 9.88 (s, 1H, H17d), 9.67 (s, 1H,
H5′), 9.03 (d, 1H, J = 5.39 Hz, H18′), 8.89 (t, 1H, J = 5.93 Hz, H8d),
8.32 (d, 1H, J = 1.69 Hz, H8′), 7.96 (t, 1H, J = 7.65 Hz, H16′), 7.87 (d,
2H, J = 8.72 Hz, H13d + H15d), 7.81 (d, 1H, J = 7.76 Hz, H1′), 7.72 (d,
1H, J = 8.26 Hz, H4′), 7.51 (m, 2H, H3′ + H17′), 7.41 (m, 2H, H11′ +
H15′), 7.34 (m, 2H, H2(E)′ + H2(Z)′), 7.22 (dd, 1H, J = 1.8 and 8.52 Hz,
H10′), 7.15 (d, 2H, J = 8.69 Hz, H12d + H16d), 6.27 (t, 1H, J = 5.79 Hz,
H2d or H4d), 6.14 (t, 1H, J = 5.66 Hz, H2d or H4d), 6.06 (d, 1H, J =
5.84 Hz, H1d or H5d), 5.98 (m, 2H, H3d + H1d or H5d), 5.16 (d, 1H, J =
18.15 Hz, H14′), 4.99 (d, 1H, J = 18.27 Hz, H14′), 4.92 (d, 1H, J =
13.99 Hz, H7′), 4.76 (s, 2H, H10d), 4.42 (ddd, 2H, J = 5.86, 14.81, and
47.62 Hz, H7d), 3.69 (d, 1H, J = 14.18 Hz, H7′).
13C NMR (125.81
MHz, DMSO-d6): E isomer, δ 191.82 (C17d), 168.16 (C9d), 167.64
(C6′), 162.75 (C11d), 161.52 (C14a′), 155.37 (C18′), 140.07 (C16′),
136.50 (C11a′), 135.78 (C4a′), 135.35 (C12a′), 132.17 (C13d + C15d),
130.67 (C14d), 129.39 (C3′), 128.66 (C7b′), 127.75 (C1′), 125.43 (C2′,
C10′, or C17′), 125.34 (C2′, C10′, or C17′), 124.74 (C2′ or C10′), 122.31
(C4′), 122.19 (C12b′), 121.23 (C8′ or C15′), 121.18 (C8′ or C15′),
115.67(C12d + C16d), 114.18 (C11′), 112.61 (C9′), 107.21 (C7a′), 103.28
(C6d), 90.03 (C2d or C4d), 89.49 (C2d or C4d), 82.49 (C1d or C5d),
81.97 (C1d or C5d), 80.78 (C3d), 67.27 (C10d), 62.52 (C14′), 40.71
(C7d), 24.02 (C7′).
13C NMR (125.81 MHz, DMSO-d6): Z isomer, δ
191.82 (C17d), 168.36 (C9d), 165.62 (C6′), 162.87 (C11d), 160.54
(C14a′), 155.24 (C18′), 139.65 (C16′), 136.44 (C11a′), 136.13 (C4a′),
133.89 (C12a′), 132.17 (C13d + C15d), 130.67 (C14d), 128.75 (C7b′),
128.48 (C3′), 127.55 (C1′), 125.15 (C2′, C10′, or C17′), 124.98 (C2′,
C10′, or C17′), 124.85 (C2′, C10′, or C17′), 123.57 (C4′), 123.08 (C8′),
122.56 (C12b′), 121.12 (C15′), 115.73 (C12d + C16d), 113.37 (C11′),
111.69 (C9′), 109.13 (C7a′), 102.16 (C6d), 88.96 (C2d or C4d), 88.29
(C2d or C4d), 83.19 (C1d or C5d), 82.28 (C1d, C5d, or C3d), 81.74 (C1d,
C5d, or C3d), 67.41 (C10d), 62.68 (C14′), 40.71 (C7d), 32.77 (C7′).
15N
NMR (50.70 MHz, DMSO-d6): E isomer, δ 109.42 (N12′), 107.95
(N5′), 88.39 (N8d).
15N NMR (50.70 MHz, DMSO-d6): Z isomer, δ
107.95 (N12′), 107.46 (N5′), 88.39 (N8d).
b. NMR Characterization of E/Z Isomers in MeOH-d4.
1H NMR
(500.32 MHz, MeOH-d4): E isomer, δ 9.87 (s, 1H, H17d), 9.42 (s, 1H,
H5′), 9.08 (d, 1H, J = 5.13 Hz, H18′), 8.11 (d, 1H, J = 1.72 Hz, H8′),
8.06 (t, 1H, J = 7.76 Hz, H16′), 7.88 (d, 2H, J = 8.81 Hz, H13d + H15d),
7.84 (dd, 1H, J = 1.46 and 7.58 Hz), 7.70 (d, 1H, J = 7.79 Hz, H15′),
7.54 (t, 1H, J = 6.66 Hz, H17′), 7.45−7.33 (m, 3H), 7.29 (m, 2H, H4′ +
1H), 7.12 (d, 2H, J = 8.76 Hz, H12d + H16d), 5.94 (t, 1H, J = 5.81 Hz,
H2d, H3d, or H4d), 5.78 (d, 1H, J = 17.1 Hz, H14′), 5.75−5.72 (m (d +
t), 2H), 5.66 (t, 1H, J = 5.67 Hz, H2d, H3d, or H4d), 5.56 (d, 1H, J =
5.88 Hz, H1d or H5d), 5.29 (d, 1H, J = 17.01 Hz, H14′), 4.90 (d, 1H, J =
15.08 Hz, H7′), 4.64 (d, 2H, J = 2.99 Hz, H10d), 4.13 (dd, 2H, J = 13.07
and 50.57 Hz, H7d), 3.29 (d, 1H, J = 14.81 Hz, H7′) [based only on the
1H,1H ROESY NMR plot and due to absence of NH signals (except
H5), protons H1, H2, H3, H10, and H11 (5H) were not assigned].
1H
NMR (500.32 MHz, MeOH-d4): Z isomer, δ 9.84 (s, 1H, H17d), 8.99
(d, 1H, J = 5.24 Hz, H18′), 8.35 (d, 1H, J = 1.73 Hz, H8′), 7.92 (t, 1H, J
= 7.68 Hz), 7.85 (d, 2H, J = 8.78 Hz, H13d + H15d), 7.79 (dd, 1H, J =
1.44 and 7.82 Hz), 7.61 (d, 1H, J = 8.11 Hz), 7.49 (t, 1H, J = 6.95 Hz),
7.45−7.33 (m, 4H, H15′ + H17′ + 2H), 7.23 (dd, 1H, J = 1.86 and 8.6
Hz), 7.18 (d, 2H, J = 8.74 Hz, H12d + H16d), 6.21 (t, 1H, J = 5.75 Hz,
H2d, H3d, or H4d), 6.05 (t, 1H, J = 5.68 Hz, H2d, H3d, or H4d), 6.03 (d,
1H, J = 5.99 Hz, H1d or H5d), 5.92 (d, 1H, J = 6.13 Hz, H1d or H5d),
5.89 (t, 1H, J = 5.55 Hz, H2d, H3d, or H4d), 5.11 (d, 1H, J = 18.09 Hz,
H14′), 4.97 (d, 1H, J = 14.08 Hz, H7′), 4.92 (d, 1H, J = 17.77 Hz, H14′),
4.82 (m, 2H, H10d), 4.59 (m, 2H, H7d), 3.69 (d, 1H, J = 13.95 Hz, H7′)
[based only on the 1H,1H ROESY NMR plot and due to the absence
of NH signals, protons H1, H2, H3, H4, H10, H11, and H16 (7H) were
not assigned].
Table 1. Crystal Data and Details of Data Collection for [RuCl2(η
6-arene)(DMSO)]·0.5H2O, L2·DMSO, cis,cis-
[RuIICl2(DMSO)2(L1)]·H2O, and mer-[RuIICl(DMSO)3(L2−H)]·H2O
[RuCl2(η
6-arene)DMSO]·0.5H2O L2·DMSO [Ru
IICl2(DMSO)2(L1)]·H2O [Ru
IICl(DMSO)3(L2−H)]·H2O
empirical formula C18H22Cl2NO4.5RuS C15H14BrN5OS C17H23Cl2N5O3RuS2 C19H27BrClN5O4RuS3
fw 528.40 392.28 581.49 702.07
space group P1 ̅ P21/c P1̅ P21/c
a [Å] 8.5676(4) 8.5399(4) 7.8726(6) 11.8408(9)
b [Å] 10.8811(4) 10.2371(6) 11.1638(9) 12.9306(10)
c [Å] 11.4797(5) 18.5633(11) 13.0422(10) 17.9286(2)
α [deg] 72.819(2) 97.546(5)
β [deg] 89.461(3) 94.712(4) 94.461(5) 108.707(4)
γ [deg] 77.030(2) 106.202(5)
V [Å3] 994.49(7) 1617.39(15) 1083.29(15) 2600.0(3)
Z 2 4 2 4
λ [Å] 0.710 73 0.710 73 0.710 73 0.710 73
ρcalcd [g cm
−3] 1.765 1.611 1.194 2.520
cryst size [mm3] 0.20 × 0.04 × 0.02 0.38 × 0.14 × 0.08 0.10 × 0.08 × 0.08 0.20 × 0.10 × 0.01
T [K] 100 100 100 100
μ [mm−1] 1.189 2.682 1.194 2.520
R1a 0.0461 0.0428 0.0519 0.0355
wR2b 0.1264 0.0978 0.1390 0.0817
GOFc 1.094 0.965 1.005 0.994
aR1 = ∑||Fo| − |Fc||/∑|Fo|. bwR2 = {∑[w(Fo2 − Fc2)2]/∑[w(Fo2)2]}1/2. cGOF = {∑[w(Fo2 − Fc2)2]/(n − p)}1/2, where n is the number of
reflections and p is the total number of parameters refined.
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Crystal Structure Determinations. X-ray diffraction measure-
ments were performed on a Bruker X8 APEX II CCD diffractometer.
Single crystals were positioned at 35, 40, 35, and 35 mm from the
detector, and 1335, 752, 2025, and 1096 frames were measured, each
for 60, 50, 60, and 60 s over a 1° scan width for [RuCl2(η
6-
a r e n e ) ( D M S O ) ] · 0 . 5 H 2 O , L 2 · D M S O , c i s , c i s -
[RuIICl2(DMSO)2(L1)]·H2O, and mer-[Ru
IICl(DMSO)3(L2−
H)]·H2O, respectively. The data were processed using SAINT
software.28 Crystal data, data collection parameters, and structure
refinement details are given in Table 1. The structures were solved by
direct methods and refined by full-matrix least-squares techniques.
Non-H atoms were refined with anisotropic displacement parameters.
H atoms were inserted into calculated positions and refined with a
riding model. One of the chloride ligands in [RuCl2(η
6-arene)-
DMSO]·0.5H2O was found to be disordered over two positions with
sof = 0.57:0.43. The structure solution was achieved with SHELXS-97
and refinement with SHELXL-97,29 and graphics were produced with
ORTEP-3.30
Conjugation of Complexes to rHSA. rHSA (50 mg mL−1) was
purchased as a 5% solution in phosphate-buffered saline (PBS;
containing 4 mM sodium caprylate and 4 mM acetyltryptophan; New
Century Pharmaceuticals Inc., Huntsville, AL) and was purified by
ultrafiltration using Centricon YM-10 (Amicon Bioseparations,
Millipore Corp.) against the modification buffer (PBS, pH 7.4). The
concentration of the protein was determined using the Bradford assay
(Bio-Rad) using bovine serum albumin as the reference protein. The
purified protein (33.2 mg of protein mL−1) was shaken with a solution
of succinyl HCl terephthalic hydrazine (SHTH; 10 equiv) in DMF (50
μL) for 16 h at room temperature such that the DMF volume did not
exceed 5% (v/v). The reaction mixture was then ultrafiltered against
the conjugation buffer (100 mM MES, 0.9% NaCl, pH 6.0), and the
concentration of the modified protein was determined using the
Bradford assay. The modified protein solution (7 mg of protein mL−1)
was added to solutions of the complex (1c−5c) in order to achieve a
3:1 metal/protein ratio and shaken for 6 h at room temperature.
Afterward, the protein mixture solution was desalted and restored in
PBS as described above. The concentration of conjugated rHSA−
complex conjugate in PBS was determined using the Bradford assay to
be 2 × 10−4 M protein.
Matrix-Assisted Laser Desorption Ionization Time-of-Flight
Mass Spectrometry (MALDI-TOF-MS) Analyses. The rHSA
samples were characterized by MALDI-TOF-MS using an Axima
CFR-Plus (Shimadzu Biotech) mass spectrometer. The samples were
prepared using the dried droplet method with freshly prepared
sinapinic acid [20 mg mL−1 in CH3CN/H2O/trifluoroacetic acid
(50:49.9:0.1)] as the matrix solution. The protein sample solution (0.5
mL, series of 1:10 dilutions) was mixed on the target with the matrix
solution (0.5 mL) and allowed to air-dry. The MS spectra were
recorded in the m/z 100−80 000 range in a positive linear mode.
External calibration was carried out with a mixture of five proteins.
Data interpretation was performed using the Kompact v2.4.3 software.
Cell Culture and Inhibition of Cell Growth. Human CH1
(ovarian carcinoma) cells were donated by Lloyd R. Kelland, CRC
Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton,
U.K. Human A549 (nonsmall cell lung carcinoma) and SW480 (colon
carcinoma) cells were provided by Brigitte Marian, Institute of Cancer
Research, Department of Medicine I, Medical University of Vienna,
Austria. Cells were grown as adherent cultures in 75 cm2 flasks (Iwaki)
in Minimal Essential Medium (MEM) supplemented with 10% heat-
inactivated fetal bovine serum, 1 mM sodium pyruvate, 1%
nonessential amino acids (100×), and 2 mM L-glutamine (all from
Sigma-Aldrich Austria) without antibiotics at 37 °C under a moist
atmosphere containing 5% CO2 and 95% air. Cytotoxicity was
determined by the MTT assay [MTT = 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide]. For this purpose, cells were
harvested from culture flasks by trypsinization and seeded in aliquots
of 100 μL well−1 into 96-well microculture plates (Iwaki) in the
following cell densities to ensure exponential growth of untreated
controls throughout drug exposure: 4 × 103 (A549), 1 × 103 (CH1)
and 2.5 × 103 (SW480) cells well−1. Cells were allowed for 24 h to
settle and resume exponential growth and were then exposed to the
test compounds by the addition of 100 μL well−1 aliquots of
appropriate dilutions in complete culture medium. For this purpose,
DMSO stocks of the compounds were diluted in the medium such that
the actual DMSO content in the tested solutions did not exceed 0.5%.
After exposure for 96 h, the medium was replaced with 100 μL well−1
RPMI 1640 medium plus 20 μL well−1 MTT dissolved in PBS (5 mg
mL−1). After 4 h, the medium/MTT mixture was replaced with 150
μL well−1 DMSO to dissolve the formazan precipitate formed by viable
cells. Optical densities at 550 nm (corrected for unspecific absorbance
at 690 nm) were measured with a microplate reader (Tecan Spectra
Classic) to yield relative quantities of viable cells as percentages of
untreated controls, and 50% inhibitory concentrations (IC50) were
calculated by interpolation. Evaluation is based on at least three
independent experiments, each comprising triplicate samples.
Human A2780 and A2780cisR ovarian carcinoma cell lines were
obtained from the European Centre of Cell Cultures (ECACC,
Salisbury, U.K.) and maintained in a culture as described by the
provider. The cells were routinely grown in RPMI 1640 medium
containing 10% fetal calf serum and antibiotics at 37 °C and 6% CO2.
For evaluation of the growth inhibition tests, the cells were seeded in
96-well plates (Costar, Integra Biosciences, Cambridge, MA) and
grown for 24 h in the complete medium. The stock solutions of the
ruthenium complexes were prepared by dissolving the compounds in 1
mL of DMSO to reach a concentration of 10−2 M. They were then
diluted in a RPMI medium and added to the wells (100 μL) to obtain
a final concentration ranging between 0 and 200 μM. DMSO at
comparable concentrations did not show any effects on cytotoxicity.
rHSA−ruthenium conjugates (2 × 10−4 M) were directly added to the
cell culture to achieve a final concentration ranging from 0 up to 100
μM. After 72 h of incubation at 37 °C, 20 μL of a solution of MTT in
PBS (2 mg mL−1) were added to each well, and the plates were then
incubated for 2 h at 37 °C. The medium was then aspirated, and
DMSO (100 μL) was added to dissolve the precipitate. The
absorbance of each well was measured at 580 nm using a 96-well
multiwell-plate reader (iEMS Reader MF, Labsystems, Bioconcept,
Switzerland) and compared to the values of control cells incubated
without complexes. The IC50 values for the inhibition of cell growth
were determined by fitting the plot of the percentage of surviving cells
against the drug concentration using a sigmoidal function (Origin
v7.5).
Cell Cycle Analysis. The effects of the compounds on the cell
cycle of human cancer cells were studied by flow cytometric analysis of
the relative DNA content of cells. For this purpose, CH1 cells were
harvested from culture flasks by using trypsin, seeded in complete
MEM into 90-mm Petri dishes (1 × 106 cells dish−1), and allowed to
recover for 24 h. Cells were then exposed for 24 h to the test
compounds (diluted from DMSO stocks with complete medium),
collected by scratching, washed with PBS, and stained with 5 μg mL−1
propidium iodide overnight. The fluorescence of 2.5 or 3.0 × 104 cells
per sample was measured with a FACSCalibur instrument, and the
obtained histograms were analyzed with CellQuest Pro software (both
from Becton Dickinson, Franklin Lakes, NJ). At least two independent
experiments were performed for each setting.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of Complexes. The
metal-free ligands (L1−L5) and [RuCl(μ-Cl)(η6-arene)]2
(where arene is 4-formylphenoxyacetyl-η6-benzylamide) were
prepared via various multistep reaction pathways. The 3-(1H-
benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines were obtained
in seven (L1), eight (L2), or eleven (L3) steps by modified
literature procedures (Scheme S1 in the Supporting Informa-
tion).25 Indolo[3,2-d]benzazepines (L4 and L5) were synthe-
sized in five steps, as described elsewhere (Scheme S2 in the
Supporting Information).21,22 [RuCl(μ-Cl)(η6-arene)]2 was
obtained in four steps, as reported in the literature (Scheme
S3 in the Supporting Information).11 Finally, the ligands (L1−
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L5) were reacted with the ruthenium(II) dimer in a 2:1 molar
ratio in ethanol under reflux to give [RuCl(η6-arene)(L)]Cl (1c
and 3c−5c) in quantitative yield. In the case of L2, the reaction
carried out under similar conditions resulted in the formation of
[RuCl(η6-arene)(L2−H)] (2c−HCl), which was further con-
verted into 2c by acidification with HCl.
ESI-MS spectra of 1c−5c in MeOH show peaks correspond-
ing to ions [M − Cl]+ and [M − HCl − H]−, confirming their
structures. Additional peaks resulting from the loss of the
chlorido ligand along with concomitant deprotonation of the
organic ligands, namely, [M − HCl − Cl]+ and [M − 2HCl −
H]−, are observed with peaks attributed to [M − HCl + Na]+
ions.
NMR spectra of 1c−4c and 2c−HCl show one set of signals,
whereas complex 5c was found to undergo E/Z isomerization
at the exocyclic amidine bond (C6′N13′) in solution (Chart
2). Analogous behavior was documented recently for [MCl(η6-
p-cymene)(L5)]Cl (where M = Ru, Os).21 The full assignment
of proton, nitrogen, and carbon resonances for [RuCl(μ-
Cl)(η6-arene)]2 and 1c−5c is given in Tables S1−S6 in the
Supporting Information.
The E/Z isomerization of 5c is solvent-dependent; the
relative intensities of the two signal sets for 5c in DMSO-d6
change from 1:0.6 immediately after dissolution to 1:2.4 at
equilibrium after 48 h. According to the 1H,1H ROESY NMR
plot, the predominant signal set at equilibrium belongs to the Z
isomer, which shows H14′,H5′ cross-peaks (Figure S7 in the
Supporting Information). In MeOH-d4, the E/Z equilibrium for
5c is reached faster than that in DMSO-d6 and the relative
abundance of E and Z isomers changes from 1:0.5 to 1:0.36 in 3
h (1:0.33 after 24 h). The dominant E isomer was identified
due to the 1H,1H ROESY NMR couplings of H5′ with arene
protons (H1d−H5d), as well as H7′ with H14′. The Z isomer
shows cross-peaks of H7′ with arene protons (H1d−H5d). It
should be noted that only one NH (H5′) signal, originating
from the E isomer, is present in the 1H NMR spectrum after
dissolution in MeOH-d4. This dissapears gradually (the
intensity decreases by a factor of 10.8 after 3 h, 65 after 9 h
to zero after 14 h).
Dissociation of the complexes may be excluded because the
chemical shifts of both signal sets differed from that of metal-
free L5 (Table S5 in the Supporting Information). Moreover,
these two sets were not affected by excess chloride ions in
MeOH-d4, providing evidence against solvolysis of the Ru−Cl
bond. Thus, at equilibrium the Z isomer dominates in DMSO-
d6, whereas the E isomer dominates in MeOH-d4, in line with
reported data for [MCl(η6-p-cymene)(L5)]Cl.21
The coordination of the ligands (L1−L5) to the ruthenium-
(II) arene moiety results in significant changes to the
resonances of both the ligands and η6-arene. For instance,
significant upfield shifts were observed for the resonances of the
η6-phenyl fragment protons H1d, H5d, H2d, and H4d of 4-
formylphenoxyacetyl-η6-benzylamide in 4c and 5c (E isomer)
compared to those in [RuCl(μ-Cl)(η6-arene)]2, whereas they
are shifted downfield in 1c−3c, 2c−HCl, and 5c (Z isomer); the
resonance of the H3d proton in all complexes is shifted
downfield.
The number of signals in the 1H NMR spectra of 1c−3c and
2c−HCl is in agreement with their C1 symmetry, and five-
membered chelate cycle formation via the nitrogens N2a and
N3b is evident. The
1H,1H ROESY NMR coupling of H1b
(14.03 ppm) with the CH2 group (H10b at 4.87 ppm) in 3c
indicates stabilization of the 7b−L3 tautomer (Chart 3). The
same coordination mode was reported for [MCl(η6-p-cymene)-
(L3)]Cl (where M = Ru, Os).25
Upon coordination of L1−L3 to the ruthenium(II) arene
moiety, significant shifts were observed for the resonances of
the benzimidazole ring protons: H1b [by 1.71 (L1), 0.7 (L2 in
2c−HCl), 1.23 (L2 in 2c), 0.78 (L3) ppm] and H4b [by 0.29
ppm in 3c; the H4b and H7b proton resonances in L1 and L2 (at
7.54 and 7.75−7.77 ppm) were not assigned; the proton H4b
gives a peak at 8.1, 8.06, and 8.01 ppm for 1c, 2c, and 2c−HCl,
Chart 2. E (left) and Z (right) Isomers of 5c
Chart 3. Coordination of L3 [7b−L3 (left) and 4b′−L3 (right) Tautomers]
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respectively]. The resonance for the pyrazolopyridine proton
H1a (the proton nearest to the metal center) was not detected
in DMSO-d6 in 1c−3c.
The signals originating from benzimidazole CH C4b and
quaternary C7b carbons in 3c and the 7b−L3 tautomer are
observed near the same positions [C4b at 118.97 (7b−L3) and
117.22 (3c) ppm; C7b at 122.95 (7b−L3) and 124.54 (3c)
ppm] and differ significantly from those in the 4b′−L3
tautomer (quaternary C4b′ at 129.38 ppm; CH carbon C7b′ at
111.17 ppm). These data provide further evidence of 7b−L3
tautomer coordination to ruthenium in 3c.
The coordination of L4 results in a significant downfield shift
for the resonances corresponding to H8′ (by 0.28 ppm), H10′
(by 0.43 ppm), and H18′ (by 0.88 ppm). Carbon resonances
C14′ (166.55 ppm) and C18′ (156.61 ppm) also differ relative to
the free ligand, by 8.18 and 6.14 ppm, respectively, indicating
bidentate paullone coordination via the pyridine (N19′) and
azomethine nitrogens (N13′) to ruthenium with the formation
of a five-membered chelate ring. The azepine methylene
protons H7′ of 4c display no diastereotopic splitting (singlet at
3.61 ppm), as was the case for free L4 and [MCl(η6-p-
cymene)(L4)]Cl (M = Ru, Os).21
Ligand L5 (with an endocyclic double bond C6′N5′)
adopts a configuration with an exocyclic double bond C6′N13′
upon coordination and protonated N5′ instead of the N13′ atom
(Chart 4). As a result, the triplet corresponding to H13′ at 7.81
ppm for L5 disappears and proton H5′ of 5c emerges as a
singlet at 9.67 (Z isomer) and 9.07 (E isomer) ppm. Because of
this rearrangement of the ligand tautomeric form, a large 15N
shift for the protonated amidine N atom from 77.4 (L5) to
107.46 (Z isomer) and 107.95 ppm (E isomer) is observed
(Table S4 in the Supporting Information).
The methylene groups of the azepine ring [H7′; 3.47 and 4.77
ppm (E isomer); 3.69 and 4.92 ppm (Z isomer)] and α-
picolylamine moiety [H14′; 5.22 and 5.84 ppm (E isomer) and
4.99 and 5.16 ppm (Z isomer)] in 5c show diastereotopic
splitting, as reported for [MCl(η6-p-cymene)(L5)]Cl,21 where-
as for the L5 proton H7′, resonance, in accordance with fast
inversion of the seven-membered azepine ring, was found at
3.41 ppm as a singlet and proton H14′ gives rise to a doublet at
4.51 ppm.
The L5 ligand in 5c undergoes significant downfield shifts for
H7′ (by 0.06−1.51 ppm), H14′ (by 0.48−1.33 ppm), and H18′
[by 0.52 (Z isomer) and 0.6 (E isomer) ppm]. Carbon signals
C14′ and C18′ were shifted compared to those of the free ligand
by 15.24 (Z isomer), 15.08 (E isomer), 5.57 (Z isomer), and
5.7 (E isomer) ppm, indicating bidentate paullone coordination
via the nitrogens N19′ and N13′ to the ruthenium center, as
reported for [MCl(η6-p-cymene)(L5)]Cl.21
Cross-peaks of high intensity in the 1H,1H ROESY NMR
spectra of 1c−3c between the η6-arene ring protons H1d, H5d,
H2d, and H4d and the nearest benzimidazole H4b proton reveal
strong couplings. Thus, the 4-formylphenoxyacetyl-η6-benzyla-
mide in 1c−3c in a DMSO-d6 solution must be oriented in
such a manner that its substituent R, or H3d, lies above the
chelate ring (Figure S8 in the Supporting Information). The
closest η6-arene ring pyrazolopyridine proton H1a was not
observed in 1c−3c in DMSO-d6. Similar solution structures
were suggested for [MCl(η6-p-cymene)(L)]Cl (M = Ru, Os; L
= L1−L3).25 Note that orientation of the cymene ring with the
isopropyl group above the chelate ring is the preferred
orientation in the crystal structures.25
The structures of 4c and 5c in DMSO-d6 were determined
from 1H,1H ROESY NMR plots and were compared with the
solution and X-ray structures of [MCl(η6-p-cymene)(L)]Cl.21
The X-ray structures of p-cymene analogue complexes facilitate
the interpretation of the solution structures of 4c and 5c (E/Z
isomers). The cross-peak originating from H8′,H14′ is more
intense than that of H10′,H14′ (i.e., the H14′ proton is closer to
H8′ than H10′), thus the chelating moiety in 4c is rotated out of
the plane of the paullone indole ring with a torsion angle ΘC14′−
N13′−C9′−C10′ > 90°, as observed in [MCl(η
6-p-cymene)(L4)]Cl21
(Figure S9 in the Supporting Information). The orientation of
the 4-formylphenoxyacetyl-η6-benzylamide group in 4c may be
deducted from the intensity of the 1H−1H ROESY cross-peaks
between protons of the paullone ligand (H8′, H10′, and H18′)
and those of the η6-arene ring. Despite the absence of cross-
peaks of H14′ with H3d and H7d and the same intensities of the
cross-peaks between H18′ and η
6-arene ring protons, the most
intense couplings, H8′, H10′ with H1d, H5d, assume the η
6-arene
ring orientation preferably with a substituent R above the
chelate ring away from the pyridine ring. Couplings H8′,H7d and
H10′,H7d are in accordance with the proposed η
6-arene
orientation (Figure S10 in the Supporting Information).
The arene ligand orientation with its substituent above the
chelate ring was also observed in a DMSO-d6 solution for 5c.
For example, the H14′ protons of both isomers oriented toward
the arene ring (at 5.16 ppm for the Z isomer and at 5.22 ppm
for the E isomer) show couplings with H7d (Figure S11 in the
Supporting Information). The intensity of the cross-peaks in
the 1H,1H ROESY NMR plot between protons of the paullone,
H18′, and the η
6-arene ring indicates a strong coupling between
H18′ and H1d/H5d. This observation is in agreement with the η
6-
arene ring orientation with the substituent above the chelate
ring toward the pyridine ring (Figure S12 in the Supporting
Information). In the Z isomer, the azepine methylene group
(H7′) is directed toward the arene ring and shows the
1H,1H
ROESY NMR cross-peaks with η6-arene ring protons. In the E
isomer, it points away from the arene ring, and as result, there
are no 1H−1H ROESY couplings with H1d−H5d (Figure S13 in
the Supporting Information).
Solid-State Structures. The molecular structures of
[RuCl2(η
6-arene)(DMSO)], where η6-arene = 4-formylphenox-
yacetyl-η6-benzylamide, and L2·DMSO are shown in Figures
S14 and S15 in the Supporting Information, respectively.
The structures of cis,cis-[RuIICl2(DMSO)2(L1)]·H2O and
mer-[RuIICl(DMSO)3(L2−H)]·H2O are shown in Figure 1.
Selected bond distances and angles are quoted in the legend.
The complex cis,cis-[RuIICl2(DMSO)2(L1)]·H2O crystallized in
the triclinic centrosymmetric space group P1 ̅ and mer-
[RuIICl(DMSO)3(L2−H)]·H2O in the monoclinic space
Chart 4. Tautomers of L5
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group P21/c. The ruthenium center in both complexes displays
a distorted octahedral coordination geometry. In cis,cis-
[RuIICl2(DMSO)2(L1)]·H2O, a bidentate neutral ligand L1,
one DMSO, and one chloride ligand are bound to ruthenium-
(II) in the equatorial plane and one chloride and one DMSO
ligand in axial positions. Coordination of the bidentate ligand
occurs via atoms N1 and N5, and DMSO binds via S. An
intramolecular hydrogen bond N2−H···O2 is evident in the
structure of cis,cis-[RuIICl2(DMSO)2(L1)] (Figure 1, left). The
presence of a proton at N4 is corroborated by the involvement
of this atom in hydrogen-bonding interaction with Cl2i (i = −x
+ 1, −y + 1, −z + 2) [N4···Cl2i 3.123 Å].
In mer-[RuIICl(DMSO)3(L2−H)], the organic molecule acts
as a bidentate monodeprotonated ligand. The site of
deprotonation appears to be the atom N2, which does not
form short contacts to adjacent molecules. Binding to
ruthenium(II) is realized via atoms N1 and N5. The other
two positions in the equatorial plane are occupied by the Cl1
ligand and one DMSO, while as axial ligands act two DMSO
molecules. All three molecules of DMSO are arranged
meridionally and bound to the central atom via S.
Preparation of rHSA Conjugates of 1c−5c. The
functionalization of the rHSA protein was carried out using
established protocols (see the Experimental Section for full
details). The protein was modified with the SHTH linker,
which reacts with amine groups on the lysine residues of the
protein. Because excess modification of the hydrophobic linkers
can result in the precipitation of the protein, the optimal
reaction conditions were determined to be within 5-fold
stoichiometric excess of the linker molecule. Upon modifica-
tion, the protein was purified and conjugated with the
ruthenium compound (3:1 metal/protein ratio) in PBS (pH
7.4), allowing sample incubation for 6 h at room temperature.
The samples were then analyzed by MALDI-TOF-MS. A
representative MALDI-TOF-MS spectrum obtained on rHSA
samples incubated with 5c is reported in Figure 2 in
comparison to the spectrum of pure rHSA. The reaction of
5c with the protein appears to be quantitative, and the main
peak at about 67 980 Da clearly indicates an increase of
approximately 1600 Da with respect to the one of rHSA, most
likely corresponding to the presence of about two bound
ruthenium moieties.
Cytotoxicity Studies. The antiproliferative activity of all
compounds was tested in the human cancer cell lines CH1,
SW480, and A549. The IC50 values of 1c−5c were compared to
those of [RuCl(μ-Cl)(η6-arene)]2, free ligands (L1−L3), and
corresponding [RuCl(η6-p-cymene)(L)]Cl complexes (1a−5a;
Table 2). It should be noted that, as a general trend, the
resulting ruthenium complexes are less cytotoxic than the free
ligands. However, the observed antiproliferative effects indicate
Figure 1. ORTEP views of cis,cis-[RuIICl2(DMSO)2(L1)] with an intramolecular hydrogen bond N2−H···O2 [N2−H 0.88, H···O2 2.151, N2···O2
2.822 Å, N2−H···O2 132.6°] (left) and mer-[RuIICl(DMSO)3(L2−H)] (right) and thermal ellipsoids drawn at the 50% probability level. Selected
bond lengths (Å) and angles (deg): (a) cis,cis-[RuIICl2(DMSO)2(L1)], Ru−N1 2.057(4), Ru−N5 2.137(4), Ru−Cl1 2.4141(14), Ru−Cl2
2.4604(14), Ru−S1 2.2352(15), Ru−S2 2.2598(14) Å, N1−Ru−N5 76.95(17), ΘN1−C6−C7−N5 6.7(7)°; (b) mer-[RuIICl(DMSO)3(L2−H)], Ru−N1
2.049(4), Ru−N5 2.135(3), Ru−Cl1 2.4228(11), Ru−S1 2.2878(11), Ru−S2 2.2834(12), Ru−S3 2.3485(11) Å, N1−Ru−N5 77.98(13),
ΘN1−C6−C7−N5 −3.5(6)°.
Figure 2. MALDI-TOF-MS spectra of rHSA and rHSA−5c conjugate.
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a marked selectivity of the ruthenium compounds toward a
cancer cell line compared to the ligands L1−L3 (e.g., complex
2c is more than 10-fold more active in the CH1 cell line than in
SW480 and A549 cells). Indeed, the ruthenium complexes
showed the strongest effects in the generally quite chemo-
sensitive ovarian carcinoma cell lines CH1, whereas the
generally more chemoresistant nonsmall cell lung cancer cell
line A549 is the least sensitive to this series of compounds.
Concentration−effect curves of 1c−5c and [RuCl(μ-Cl)(η6-
arene)]2 in the CH1 cells are depicted in Figure S19 in the
Supporting Information. While the rank order of the
cytotoxicity of the analogous cymene complexes with 3-(1H-
benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines is in line with
the cytotoxicity of the free ligands, 3a > 2a > 1a corresponding
to L3 > L2 > L1, indicating that both the bromo and
methoxymethyl substituents are advantageous for cytotoxic
potency, the structure−activity relationship of 1c−3c is less
clear-cut, which may be caused by the borderline solubility
associated with the presence of the 4-formylphenoxyacetyl-η6-
benzylamide ligand. In the SW480 and A549 cells, complexes
1c−3c show no antiproliferative activity in concentrations up to
320 μM, and neither do 4c and [RuCl(μ-Cl)(η6-arene)]2 in the
A549 cells. The most active of the complexes bearing a 4-
formylphenoxyacetyl-η6-benzylamide ligand is the paullone
complex 5c with IC50 values of 29 μM in CH1 cells, 49 μM
in SW480 cells, and 123 μM in A549 cells. This paullone
complex with a derivatized lactam unit (5c) shows higher
antiproliferative activity than the paullone complex with
unmodified lactam group (4c) in all three cell lines, as was
reported for [RuCl(η6-p-cymene)(L)]Cl complexes 4a and 5a
(as well as their osmium analogues) with paullones L4 and
L5.21
The impact of tethering 1c−5c to rHSA on their antitumor
activity in vitro was evaluated in ovarian carcinoma cell line
either sensitive (A2780) or resistant to cisplatin (A2780cisR).
Table 3 reports the IC50 values obtained for inhibition of the
A2780 and A2780cisR cell growth upon treatment with
compounds 1c−5c and their rHSA conjugates. As expected
from the cytotoxicity data reported above, the ruthenium
complexes alone did not significantly affect the cell growth
within the tested concentration range, with the most effective
being 5c, whereas a marked response was observed in the case
of the rHSA−ruthenium conjugates. In the case of rHSA−5c,
IC50 values of 26 and 28 μM were observed in the two cell lines,
indicating that the conjugation strategy overcomes the
resistance mechanism that blocks entry and/or increases efflux
of cisplatin from the cells.
It is worth mentioning that the potential of macromolecular
metal complexes to overcome resistance mechanisms has
already been investigated with platinum compounds.31 In this
case, the results showed that albumin binding lowers the
cytotoxic activity of platinum complexes in cancer cell lines.
However, the HSA−Pt conjugates exhibited comparable
activity in the sensitive and cisplatin-resistant cells.
Because the rHSA conjugates contain more than one
ruthenium, the increase in the cytotoxicity is not extremely
large, but it should be noted that the rHSA conjugates should
exploit the so-called “enhanced permeability and retention
(EPR)” effect of macromolecules on tumors32 and, con-
sequently, should selectively accumulate in tumor tissue. The
EPR effect is based on the observation that macromolecules are
able to penetrate the leaky vasculature surrounding the tumor,
and as a result of the increased permeability, the macro-
molecules “selectively” permeate the tumor tissues compared to
the healthy tissues. In addition, the lymphatic drainage system
of tumor tissue is impaired, resulting in accumulation of the
macromolecules at the tumor site.
Cell Cycle Effects. To study the effects of the compounds
on cell cycle distribution in the sensitive ovarian cancer cell line
CH1, cells were treated for 24 h, stained with propidium iodide,
and analyzed for their DNA content by fluorescence-activated
cell sorting (FACS). These experiments revealed that
complexes 4c and 5c with indolobenzazepine-derived ligands
L4 and L5, respectively, induce stronger cell cycle perturbations
than 2c with a pyrazolopyridine-derived ligand (L2; Figure 3).
In particular, treatment with 5c caused a pronounced G2/M
phase arrest in concentrations up to 80 μM (81 ± 4% of cells in
G2/M compared to 36 ± 4% in untreated controls),
accompanied by a steady decrease of the G1/G0 fraction, but
Table 2. Cytotoxicity of 1c−5c, Compared to [RuCl(μ-
Cl)(η6-arene)]2, Free Ligands (L1−L3), and Corresponding
[RuCl(η6-p-cymene)(L)]Cl Complexes (1a−5a), in Three
Human Cancer Cell Lines
IC50,
a μM
compound CH1 SW480 A549
[RuCl(μ-Cl)(η6-arene)]2 65 ± 21 215 ± 35 >320
L1b 11 ± 3 23 ± 6 29 ± 7
1ab 96 ± 18 >320 >320
1c 142 ± 33 >320 >320
L2b 1.5 ± 0.6 5.1 ± 1.0 6.7 ± 0.3
2ab 21 ± 3 70 ± 8 268 ± 35
2c 32 ± 13 >320 >320
L3b 0.63 ± 0.09 0.74 ± 0.26 5.2 ± 0.5
3ab 11 ± 1 11 ± 2 68 ± 12
3c 153 ± 42 >320 >320
L4
4ac 9.7 ± 1.6 28 ± 5 32 ± 1
4c 55 ± 15 179 ± 24 >320
L5
5ac 1.9 ± 0.4 1.2 ± 0.5 8.5 ± 0.7
5c 29 ± 2 49 ± 2 123 ± 20
a50% inhibitory concentrations (means ± standard deviation from at
least three independent experiments), as obtained by the MTT assay
(exposure time: 96 h). bTaken from ref 25. cTaken from ref 21.
Table 3. Inhibition of Human Ovarian Carcinoma Cell
Growth (IC50, μM) for 1c−5c and Their rHSA Conjugates
after 72 h of Incubation
IC50, μM
compound A2780 A2780cisR
rHSA >75a
rHSA−hydrazine >75a
1c >200 >200
rHSA−1c 45 ± 5 67 ± 3
2c >200 >200
rHSA-2c 43 ± 3 >100
3c >200 >200
rHSA−3c 46 ± 2 69 ± 6
4c >100 >100
rHSA−4c 49 ± 2 43 ± 2
5c 85 ± 4 66 ± 7
rHSA−5c 26 ± 2 28 ± 1
aTaken from ref 11.
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superseded by an S phase arrest at 160 μM (52 ± 0.3% of cells
in the S phase). In addition, the appearance of a pronounced
sub-G1/G0 fraction (excluded from analysis) and the
tremendous decrease of the G2/M fraction (27 ± 6%) at this
highest concentration suggest that apoptotic cell death is
preferentially induced in G2/M cells. In accordance with the
slightly lower cytotoxicity in the MTT assay, 4c is also
somewhat less effective on the cell cycle. Neither an S phase
arrest nor a comparable sub-G1/G0 fraction could be observed
at the highest concentration, but the compound as well induces
a G2/M arrest reaching 68 ± 1% at 160 μM. In conclusion, the
differences in the position of the chelating moiety in 4c and 5c
(whether on the lactam ring or not) seem to merely modulate
the antiproliferative potency of the compounds rather than
fundamentally change the capacity of inhibiting cell cycle
progression.
Final Remarks. Herein we describe the synthesis and
characterization of a new series of organometallic complexes of
the general formula [RuCl(η6-arene)(L)]Cl [where L = 3-(1H-
benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines and indolo-
[3,2-d]benzazepines (L1−L5), which are potential kinase
inhibitors]. Complexation of L1−L5 to the ruthenium(II)
arene unit yielded compounds with increased solubility in
biological media, yet lower, but more selective antiproliferative
activity in human cancer cell lines. In order to improve the mild
cytotoxic effects of the ruthenium derivatives, we coupled the
compounds to serum albumin, which is known to accumulate
in tumors. HSA has previously been used to deliver various
anticancer drugs such as chlorambucil, doxorubicin, paclitaxel,
and cisplatin to cancer cells.33 Chlorambucil− and paclitaxel−
HSA conjugates exhibit cytotoxicity comparable to that of the
parent drugs in vitro but are less toxic in vivo,26,27 and a
doxorubicin prodrug using endogenous serum albumin as a
drug carrier displays excellent in vivo properties.34,35
Thus, the five organometallic complexes were conjugated to
rHSA, tethering them to the protein via pH-triggered linkers, as
previously described for the organometallic RAPTA com-
pounds that are not cytotoxic but active as antimetastatic agents
in vivo.36−38 MALDI-TOF-MS analysis of the rHSA−Ru
adducts showed that typically two ruthenium-containing
moieties were bound to the protein. The rHSA conjugates
were found to be more cytotoxic than the “free” complexes on
human ovarian cancer A2780 cell lines sensitive and resistant to
cisplatin. These results are encouraging, and the further
development of macromolecular organometallic ruthenium
complexes that should selectively target tumor tissue appears
to be worthwhile.
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